RT Journal Article
SR Electronic
T1 Developing and validating polygenic risk scores for colorectal cancer risk prediction in East Asians
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.02.14.22270878
DO 10.1101/2022.02.14.22270878
A1 Ping, Jie
A1 Yang, Yaohua
A1 Wen, Wanqing
A1 Kweon, Sun-Seog
A1 Matsuda, Koichi
A1 Jia, Wei-Hua
A1 Shin, Aesun
A1 Gao, Yu-Tang
A1 Matsuo, Keitaro
A1 Kim, Jeongseon
A1 Kim, Dong-Hyun
A1 Jee, Sun Ha
A1 Cai, Qiuyin
A1 Chen, Zhishan
A1 Tao, Ran
A1 Shin, Min-Ho
A1 Tanikawa, Chizu
A1 Pan, Zhi-Zhong
A1 Oh, Jae Hwan
A1 Oze, Isao
A1 Ahn, Yoon-Ok
A1 Jung, Keum Ji
A1 Ren, Zefang
A1 Shu, Xiao-Ou
A1 Long, Jirong
A1 Zheng, Wei
YR 2022
UL http://medrxiv.org/content/early/2022/03/15/2022.02.14.22270878.abstract
AB Importance Several polygenic risk scores (PRSs) have been developed to predict the risk of colorectal cancer (CRC); however, virtually all these PRSs were constructed in European descendants.Objective To develop and validate PRSs using data from large genome-wide association studies (GWAS) conducted in East Asians.Design, Setting, and Participants PRSs were developed using GWAS data from 22,702 cases and 212,486 controls and validated in two case-control studies (1,454 Korean and 1,736 Chinese). PRSs were derived using three approaches: (1) leading risk variants in GWAS-identified CRC loci; (2) risk variants independently associated with CRC in East Asians that were identified via fine-mapping of known GWAS-identified risk loci; and (3) genome-wide risk prediction algorisms using LDpred2 and PRS-CS.Main Outcomes and Measures Logistic regression models were used to examine associations of PRSs with CRC risk by estimating odds ratios (ORs) with 95% confidence intervals (CIs) and area under the receiver operating characteristic curve (AUC).Results In the validation sets, PRS115-EAS, a PRS with 115 GWAS-reported leading risk variants derived from East Asian data performed significantly better in discriminating CRC cases from non-cases than PRS115-EUR, a PRS derived using GWAS data from European descendants. In the Korea validation set, ORs per SD increase of PRS115-EAS were 1.63 (95%CI = 1.46 - 1.82; AUC = 0.63), compared with OR of 1.44 (95%CI = 1.29 - 1.60, AUC = 0.60) for PRS115-EUR. PRS115-EAS/EUR derived using results from meta-analyses of East Asian and European-ancestry data slightly improved the AUC to 0.64 (95% CI = 0.61 - 0.67). Similar, but less strong, associations were found in the China validation set. Individuals in the top 5% of PRS115-EAS/EUR were at a 2.52-folded (95% CI = 2.27 - 2.81) elevated risk of CRC as compared with the average risk group and have a 12% or higher risk of developing CRC by age 85 years.Conclusions and Relevance Our results indicate that PRSs derived using GWAS-identified CRC risk variants are promising in predicting CRC risk in East Asians. Our study highlights the importance of using population-specific data to build CRC risk prediction models.Question How well do polygenetic scores (PRS) developed using data from genome-wide association studies (GWAS) predict colorectal cancer (CRC) risk in East Asians?Findings Using GWAS data from more than 230,000 cases and controls in East Asian, 11 PRSs were developed with variants ranging from 115 to 747,643. PRS including 115 variants derived from meta-analyses of East Asian and European-ancestry GWAS data showed the highest performance in discriminating CRC cases and controls in validation sets including 1,490 cases and 1,700 controls.Meaning These findings support the utility of PRS in identifying high-risk individuals for CRC prevention and highlight the importance of using population-specific data to build CRC risk prediction models.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work at Vanderbilt University Medical Center was supported by U.S. NIH grants R01CA188214, R37CA070867, UM1CA182910, R01CA124558, R01CA158473, and R01CA148667, as well as Anne Potter Wilson Chair funds from the Vanderbilt University School of Medicine. Sample preparation and genotyping assays at Vanderbilt University were conducted at the Survey and Biospecimen Shared Resources and Vanderbilt Microarray Shared Resource, supported in part by the Vanderbilt-Ingram Cancer Center (P30CA068485). Statistical analyses were performed on servers maintained by the Advanced Computing Center for Research and Education (ACCRE) at Vanderbilt University (Nashville, TN). Studies (listed with grant support) participating in the Asia Colorectal Cancer Consortium include the Shanghai Women's Health Study (US NIH, R37CA070867, UM1CA182910), the Shanghai Men's Health Study (US NIH, R01CA082729, UM1CA173640), the Shanghai Breast and Endometrial Cancer Studies (US NIH, R01CA064277 and R01CA092585; contributing only controls), the Shanghai Colorectal Cancer Study 3 (US NIH, R37CA070867, R01CA188214 and Anne Potter Wilson Chair funds), the Guangzhou Colorectal Cancer Study (National Key Scientific and Technological Project, 2011ZX09307-001-04; the National Basic Research Program, 2011CB504303, contributing only controls, the Natural Science Foundation of China, 81072383, contributing only controls), the Hwasun Cancer Epidemiology Study - Colon and Rectum Cancer (HCES-CRC; grants from Chonnam National University Hwasun Hospital Biomedical Research Institute, HCRI18007), the Japan BioBank Colorectal Cancer Study (grant from the Ministry of Education, Culture, Sports, Science and Technology of the Japanese government), the Aichi Colorectal Cancer Study (Grant-in-Aid for Cancer Research, grant for the Third Term Comprehensive Control Research for Cancer and Grants-in-Aid for Scientific Research from the Japanese Ministry of Education, Culture, Sports, Science and Technology, 17015018 and 221S0001), the Korea-NCC (National Cancer Center) Colorectal Cancer Study (Basic Science Research Program through the National Research Foundation of Korea, 2010-0010276 and 2013R1A1A2A10008260; National Cancer Center Korea, 0910220), and the KCPS-II Colorectal Cancer Study (National R&D Program for Cancer Control, 1631020; Seoul R&D Program, 10526).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Internal Review Board for human subject research by Vanderbilt University Medical Center. All studies involved in the current analyses have been approved by the ethic committees of the study institutions. All participants provided informed consent prior to study inclusion.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors